MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia metabolic syndrome type 2 diabetes and non-alcoholic steatohepatitis. The compound formerly known as RWJ-800025 was licensed from Janssen Pharmaceutica NV.
This page contains content from the copyrighted Wikipedia article "MBX-8025"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
